Replies to post #670254 on NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Merck's keytruda patent expires in 2028 not 2024.

[axelvento]

Another key part of Merck’s strategy is developing a subcutaneous, or under-the-skin, formulation of Keytruda, which is currently given intravenously. Such a version could give Merck leverage to compete with any generic versions of IV Keytruda that emerge following patent expiry in 2028.

https://www.biopharmadive.com/news/merck-dealmaking-15-billion-keytruda-cliff-davis/706309/